We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Immune Checkpoint Inhibition in Hepatocellular Carcinoma: Basics and Ongoing Clinical Trials.
- Authors
Kudo, Masatoshi
- Abstract
Clinical trials of antibodies targeting the immune checkpoint inhibitors programmed cell death 1 (PD-1), programmed cell death ligand 1 (PD-L1), or cytotoxic T-lymphocyte- associated protein 4 (CTLA-4) for the treatment of advanced hepatocellular carcinoma (HCC) are ongoing. Expansion cohorts of a phase I/II trial of the anti-PD-1 antibody nivolumab in advanced HCC showed favorable results. Two phase III studies are currently ongoing: a comparison of nivolumab and sorafenib in the first-line setting for advanced HCC, and a comparison of the anti-PD-1 antibody pembrolizumab and a placebo in the second-line setting for patients with advanced HCC who progressed on sorafenib therapy. The combination of anti-PD-1/PD-L1 and anti-CTLA-4 antibodies is being evaluated in other phase I/II trials, and the results suggest that an anti-PD-1 antibody combined with locoregional therapy or other molecular targeted agents is an effective treatment strategy for HCC. Immune checkpoint inhibitors may therefore open new doors to the treatment of HCC.
- Subjects
THERAPEUTIC use of immunoglobulins; THERAPEUTIC use of monoclonal antibodies; ANTIGENS; ANTINEOPLASTIC agents; CELL receptors; CLINICAL trials; HEPATOCELLULAR carcinoma; IMMUNOTHERAPY; MONOCLONAL antibodies
- Publication
Oncology, 2017, Vol 92, p50
- ISSN
0030-2414
- Publication type
Article
- DOI
10.1159/000451016